Polymorphonuclear neutrophils (PMN) infiltrate the respiratory tract early after viral 2 2 infection and can contribute to both host defense and pathology. Coronaviruses are important 2 3 causes of respiratory tract infections, ranging from mild to severe depending on the viral strain. 2 4 This study evaluated the role of PMN during a non-fatal pulmonary coronavirus infection in the 2 5 natural host. Rat coronavirus (RCoV) causes respiratory disease in adult rats, characterized by 2 6 an early PMN response, viral replication and inflammatory lesions in the lungs, mild weight loss, 2 7 and effective resolution of infection. To determine their role during RCoV infection, PMN were 2 8 depleted and the effects on disease progression, viral replication, inflammatory response, and 2 9 lung pathology were analyzed. Compared to RCoV infection in control animals, PMN-depleted 3 0
recruitment of PMN to the respiratory tract by day 8 (Fig. 3b ). Despite the influx of PMN into 1 4 1 the airways, viral titers in the lungs remained high on day 8 ( Fig. 3c ), suggesting that the NRS-treated animals ( Fig. 3d and e ). NRS-RCoV rats initially lost weight, which they re-gained 1 4 5 after day 3 ( Fig. 3e ). Of the 6 animals that died during the study, 1 succumbed to infection on 1 4 6 day 3 and 5 were euthanized due to more than 20% weight loss and severe disease. Clinical signs 1 4 7
were apparent on days 2-8 post-infection and were identical to those seen in rats given α PMN Compared to mock-inoculated animals, RCoV infection increased levels of PMN-specific 1 7 8 chemokines (CXCL-1 and CXCL-3) in NRS-treated animals by day 4, which returned to mock 1 7 9 levels by day 8 (Fig. 5a ). In contrast, PMN-depleted rats had significantly reduced levels of 1 8 0
CXCL-1 and CXCL-3 in the BALF, which corresponded with the lack of PMN recruitment to 1 8 1 the lungs of depleted animals even after PMN had repopulated the blood ( Fig. 1b and 2a ). Two were quantified in BALF from αPMN and NRS treated rats on day 4 post-infection ( Fig. 5b ). suggesting that PMN are needed for chemokine production. Based on the data above, we hypothesize that PMN recruited to the airways of RCoV-
infected rats produce cytokines and chemokines, including CXCL-1, CXCL-3, IP-10, and CCL- cells. The mRNA levels of 84 cytokines and chemokines were measured from PMN using 1 9 7 quantitative RT-PCR arrays ( Table 1) . PMN that were incubated in RCoV-AT1 medium had 1 9 8
higher mRNA levels of proinflammatory cytokines (IL-18, IL-1α, IL-1β, and TNF-α), CXC 1 9 9
chemokines (CXCL-1, CXCL-2, IP-10, CXCL-11), and CC chemokines (CCL-2, CCL-4, CCL-2 0 0 7, CCL-9, in comparison to PMN incubated in mock-AT1 medium. These 2 0 1 findings demonstrated that PMN express proinflammatory cytokines and chemokines when 2 0 2 exposed to RCoV-infected epithelial cells. This is in agreement with the reduced concentrations The presence of PMN in the lungs is associated with tissue damage. Hemorrhagic lesions are observed on the surface of the lungs following the same kinetics 2 0 8
as PMN recruitment during RCoV infection (Funk et al., 2009) . Therefore, we determined 2 0 9
whether the presence of PMN correlated with visible lesions on the surface of rat lungs. RCoV 2 1 0 infection of NRS-treated rats resulted in gross pulmonary lesions in all animals that were 2 1 1 analyzed on day 4, and the majority of NRS-treated animals did not have lesions on day 8. The were present in the BALF, there was a corresponding increase in protein concentration (Table 2) .
Furthermore, animals that had low numbers of PMN also had low total protein concentrations in 2 2 2 the BALF. Collectively, these findings implicate PMN in causing tissue injury including gross 2 2 3 hemorrhagic lesions and epithelial permeability. epithelial sloughing ( Fig. 6b ), compared to mock-inoculated rats ( Fig. 6a ). Some alveoli of compared to the clear alveoli of uninfected rats ( Fig. 6d ). Interestingly, most of this lack of PMN was associated with epithelial and vascular pathology. to elicit an effective cellular response to control viral replication and attenuate disease severity.
4 8
Despite an effective response against RCoV, NRS-treated rats had pulmonary lesions, anti-viral responses, but also mediating tissue pathology.
5 2
A rabbit anti-rat PMN antibody was used to deplete PMN in vivo without significantly 2 5 3 affecting circulating monocytes and lymphocytes. This antibody is widely used to deplete PMN infected cells (Fujisawa, 2008; Hartshorn et al., 1994; Hashimoto et al., 2007; Tecle et al., 2007;  2 7 2
West et al., 1987) . PMN may also contribute to protection by recruitment and activation of other immune cell types (Beauvillain et al., 2007; Radsak et al., 2000; Scapini et al., 2000) . In previous studies, we showed that RCoV infects AT1 cells in the lungs and induces expression of Rzepka et al., 2012). Here, we show that PMN responded to medium from RCoV-infected AT1-2 7 7 like cells in vitro by increasing mRNA levels of proinflammatory cytokines and chemokines. airways of RCoV-infected rats. Our in vivo findings suggest that PMN are a source of 2 8 0 chemokines, including IP-10, CCL-2, CXCL-1, and CXCL-3, in the airways during RCoV 2 8 1 infection. It is also possible that PMN induce other cell types to produce these chemokines. CXCL-1 and CXCL-3 recruit and activate PMN (Rzepka et al., 2012; Shibata et al., 1995) . The lungs and airways of RCoV-infected rats, which was dramatically absent in PMN-depleted rats. We specifically found reduced numbers of CD4+ and CD8+ cells in BALF from PMN-depleted 2 9 0
animals. The numbers of circulating lymphocytes were not altered directly by α PMN treatment. Therefore, we hypothesize that the reduced numbers of lymphocytes in the respiratory tract of for effective clearance of RCoV (Weir et al., 1990) . Our data support a role for PMN in 2 9 4 recruitment of T cells to the respiratory tract, which may be responsible for viral clearance. In addition to providing protection from RCoV-mediated disease, we found that the 2 9 6 presence of PMN in the lungs was associated with histopathology, hemorrhagic lesions, and 2 9 7 increased epithelial permeability. While it seems contradictory that the animals with overt by other studies (Funk et al., 2009; Wojcinski & Percy, 1986) . A comprehensive study using the JHMV, causes increased viral titers in the brain and a more rapid decline to death compared to 3 1 3 mice with PMN (Zhou et al., 2003) . Furthermore, when a CXCR2-specific antibody is used to infections are likely dependent upon the age and strain of mice and the relative virulence of the 3 2 6 particular virus strains being studied. These parameters, which vary amongst the studies, may alter the balance between the protective and pathogenic functions of PMN. have also generated disparate conclusions depending upon the dose and strain of virus, genetic interplay between beneficial and detrimental functions of PMN will lead to novel therapeutic 3 4 6 strategies to reduce morbidity during respiratory viral infections. L2P41.a cells (Gagneten et al., 1996) as described previously (Miura et al., 2007) and mortality and surviving animals were euthanized on day 8 or 12 for tissue analyses. An days -1 and +2 with respect to the infection (Fig. 3a) . For transient depletion, 10 NRS/RCoV and Pathology 24, 11-17. Immunology and cell biology 90, 197-205. The role of neutrophils during mild and severe influenza virus infections of mice. PLoS 5 6 0 ONE 6, e17618. Tumpey, T. M., Garcia-Sastre, A., Taubenberger, J. K., Palese, P., Swayne, D. E., Pantin- Weir, E. C., Jacoby, R. O., Paturzo, F. X., Johnson, E. A. & Ardito, R. B. (1990) Widegren, H., Andersson, M., Borgeat, P., Flamand, L., Johnston, S. & Greiff, L. (2011) . LTB4 5 7 6
increases nasal neutrophil activity and conditions neutrophils to exert antiviral effects.
7 7
Respiratory medicine 105, 997-1006. differences between α PMN-and NRS-treated rats were identified using one-way ANOVA Rats were injected with α PMN or NRS intraperitoneally 1 day prior to intranasal inoculation 6 0 0
with RCoV, and every 48 h thereafter (see Fig. 1a ). (a) Cells from bronchoalveolar lavage fluid 
